Campbell & Co Investment Adviser’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-23,082
Closed -$913K – 1064
2025
Q4
$913K Buy
+23,082
New +$846K 0.04% 601
2025
Q3
– Sell
-8,681
Closed -$284K – 1082
2025
Q2
$284K Buy
+8,681
New +$282K 0.02% 976
2024
Q1
– Sell
-22,724
Closed -$811K – 1097
2023
Q4
$811K Buy
+22,724
New +$845K 0.07% 477
2023
Q2
– Sell
-23,700
Closed -$982K – 871
2023
Q1
$982K Buy
23,700
+17,872
+307% +$742K 0.18% 167
2022
Q4
$259K Buy
+5,828
New +$243K 0.06% 600
2021
Q2
– Sell
-5,527
Closed -$362K – 518
2021
Q1
$362K Buy
5,527
+1,400
+34% +$86.2K 0.22% 173
2020
Q4
$230K Buy
+4,127
New +$178K 0.14% 326
2019
Q3
– Sell
-12,254
Closed -$366K – 600
2019
Q2
$366K Buy
+12,254
New +$358K 0.17% 239
2018
Q4
– Sell
-15,339
Closed -$537K – 329
2018
Q3
$537K Buy
15,339
+4,200
+38% +$133K 0.37% 64
2018
Q2
$301K Buy
+11,139
New +$262K 0.23% 187
2017
Q4
– Sell
-9,149
Closed -$205K – 390
2017
Q3
$205K Buy
+9,149
New +$207K 0.17% 287

Other funds holding ATRC

Campbell & Co Investment Adviser's ATRC Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of AtriCure (ATRC) in Q1 2026, closing a stake of 23,082 shares — an estimated $913K sold.

Campbell & Co Investment Adviser first reported a position in ATRC in Q3 2017 and held it in 11 quarters. The position peaked at $982K in Q1 2023. 224 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining AtriCure position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 23,082 AtriCure shares in Q1 2026, an estimated $913K.
  • Campbell & Co Investment Adviser first reported a position in AtriCure in Q3 2017 and held it in 11 quarters.
  • Campbell & Co Investment Adviser's AtriCure position peaked at $982K in Q1 2023.
  • 224 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.